**Appendix 4.**

**Reference Listings**

**Chapter 1. I am Diagnosed with Prostate Cancer**

1. Bratt O, et al., **Hereditary Prostate Cancer: Clinical Aspects.** The Journal of Urology, Vol. 168, 906–913, September 2002.

**Chapter 2. What is Prostate Cancer?**

1. Australian Institute of Health and Welfare. Incidence and Prevalence of Chronic Disease, 2009. [http://www.aihw.gov.au/cdarf/data\_pages/incidence\_prevalence/index.cfm#Diabetes.](http://www.aihw.gov.au/cdarf/data_pages/incidence_prevalence/index.cfm%23Diabetes.)

**Chapter 3. How is Prostate Cancer Detected?**

1. Thompson IM, et al., **Prevalence of prostate cancer among men with a PSA level < or =4.0 ng per millilitre.** New England Journal of Medicine, 2004; 350(22): 2239-46.
2. Boots WebMD Web site. **Prostate Cancer Guide.** <www.webmd.boots.com/prostatecancer/guide/psa-test-prostate-cancer.>
3. See 1 and 2 above.
4. El Camino Urology Medical Group web site. **Prostate Cancer.** <www.elcaminourology.com/PSAandProstateCancer.html.>
5. Scosyrev, E, et al., **PSA screening for prostate cancer and the risk of overt metastatic disease at presentation: Analysis of trends over time.** Cancer. 2012 Dec 1; 118 (23):5768-76.
6. **Hunter Prostate Cancer Alliance web site.** [www.hpca.org.au/pcfmenu/testingmenu/item/51-morepsa.html#Density](www.hpca.org.au/pcfmenu/testingmenu/item/51-morepsa.html%23Density)
7. Prostate Health Index (*phi*). **FDA Approves New Blood Test to Improve Prostate Cancer Detection, June 2012.**
8. **Clinical Information about the 4K score Test**. OPKO Diagnostics. <http://clinical.opko.com/how-does-4kscore-test-work>.
9. **Pre-treatment Genetic Test Predicts Recurrence in Prostate Cancer.** [http://www.onclive.com/web-exclusives/Pretreatment-Genetic-Test-Predicts-Recurrence-in-Prostate-Cancer#sthash.jlEIkaKK.dpuf.](http://www.onclive.com/web-exclusives/Pretreatment-Genetic-Test-Predicts-Recurrence-in-Prostate-Cancer%23sthash.jlEIkaKK.dpuf.)
10. Castro E, Goh C, Saunders E, et al., **Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer.** JCO May 10, 2013 vol. 31 no. 14 1748-1757.
11. Pokorny MR, de Rooij M, et al., **Prospective Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound–Guided Biopsy Versus Magnetic Resonance (MR) Imaging with Subsequent MR-guided Biopsy in Men Without Previous Prostate Biopsies.** Eur Urol. 2014 Jul; 66(1):22-9.
12. Bonekamp D, Jacobs MA, El-Khouli R, et al., **Advancements in MR imaging of the prostate: from diagnosis to interventions.** Radiographics 31 (3 Suppl): 677–703. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093638/.](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093638/)
13. Rothwax JT, George AK, et al., **Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion-Guided.** BioMed Research International, Volume 2014, Article ID 439171.
14. Bloch BN, Genega EM, Costa DN, et al., **Prediction of prostate cancer extracapsular extension** **with high spatial resolution dynamic contrast-enhanced 3-T MRI.** Eur Radiol. 2012 Oct; 22(10): 2201-10.
15. Barentsz JO, Richenberg J, Clements R, et al., **ESUR prostate MR guidelines 2012.** European Radiology 2012 10.1007/s00330-011-2377-y.
16. Junker D, Schäfer G, Edlinger M, et al., **Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer.** BioMed Research Int. Vol. 2013 (2013), Article ID 252939.
17. McKiernan J, Donovan M, O’Neill V, et al., **A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.** JAMA Oncol. March 31, 2016. doi:10.1001/jamaoncol.2016.0097.

# Kasivisvanathan, V., et al., Prostate evaluation for clinically important disease: Sampling using image-guidance or not? (The PRECISION study). European Urology Supplements, Volume 17, Issue 2, e1716 - e1717.

**Chapter 5. Introductory Comments on Treatment Options**

1. Jani AB, Hellman S. **Early prostate cancer: clinical decision-making.** Lancet 2003 l.: 361: 1243-52.
2. Barocas DA, et al., **Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.** JAMA. 2017;317(11):1126-1140. doi:10.1001/jama.2017.1704.

**Chapter 6. Active Surveillance**

1. Ip S, Dahabreh IJ, Chung M, et al., **An evidence review of active surveillance in men with localized prostate cancer.** Evid Rep Technol Assess (Full Rep). 2011 Dec; (204):1-341.
2. Mohler JL. Roswell Park Cancer Institute and chair of the NCCN Guidelines Panel for Prostate Cancer, **Presentation at the NCCN 16th Annual Conference in the USA.**
3. Klotz L, Zhang L, Lam A., et al. **Clinical results of long-term follow-up of a large active surveillance cohort with localised prostate cancer.** J Clin Oncol 2010; 28: 126–31.
4. Sung Kyu Hong. **Clinically insignificant prostate cancers: are they really insignificant?**

<http://approstate.org/workshop/201101/program/files/APPS_Sung%20Kyu%20Hong.pdf.>

1. Wolters T, Roobol MJ, van Leeuwen PJ, et al., **A critical analysis of the tumour volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.** J Urol. 2011 Jan; 185(1): 121-5.
2. Jeldres C, Suardi N, Walz J, et al., **Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men.** Eur Urol. 2008 Dec; 54(6): 1306-13. Epub 2007 Dec 7.
3. Mottet N, Bastian PJ, Bellmunt J, et al., **Pocket Guidelines on Prostate Cancer Updated April 2014.** European Urology Association.
4. See 5 above.

**Chapter 7. Surgery**

1. Rozet F, et al., Dept of Urology, Institut Montsouris, Paris, France**. A Direct Comparison of Robotic Assisted Versus Pure Laparoscopic Prostatectomy: A Single Institution’s Experience.** <http://www.abmedica.it/Rozet%20J%20Urol%202007.pdf>
2. Lepor H. **Smilow Comprehensive Prostate Cancer Centre Web Site** <http://prostatecancer.med.nyu.edu/treatment/prostate-cancer-surgery.>
3. Walsh PC, Lepor H, Eggleston JC. **Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.** Prostate. 1983; 4(5): 473-85.
4. Marien T, Sankin A, Lepor H. **Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J** Urol. 2009 Apr; 181(4): 1817-22.
5. Jacobs EFP, Boris R, et al., **Advances in Robotic-Assisted Radical Prostatectomy over Time.** Prostate Cancer, Vol. 2013 (2013), Article ID 902686.
6. Ahlering T. Department of Urology, University of California, Irvine. [http://www.urology.uci.edu/prostate/index.html.](%20http:/www.urology.uci.edu/prostate/index.html.)
7. Australian Institute of Health and Welfare. **Incidence and Prevalence of Chronic Disease, 2009.** [www.aihw.gov.au/cdarf/data\_pages/incidence\_prevalence/index.cfm#Diabetes.](www.aihw.gov.au/cdarf/data_pages/incidence_prevalence/index.cfm%23Diabetes.)
8. Park JJ, Kim CK, Park SY, et al., **Prostate Cancer: Role of Pre-treatment Multiparametric 3-T MRI in Predicting Biochemical Recurrence After Radical Prostatectomy.** *AJR Am J Roentgenol.* 2014; 202:W459-W465.

**Chapter 8. Radiation**

1. Frank SJ, Pisters LL, Davis J, et al., **An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.** J Urol. 2007 Jun; 177(6): 2151-6; discussion 2156.
2. Prostate Cancer Foundation of Australia. **External Beam Radiotherapy.**

<http://www.prostate.org.au/articleLive/pages/External-BeamRadiotherapy.html.>

1. Feng FY, Blas K, Olson K, et al., **Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.** Int J Radiat Oncol Biol Phys. 2013 May 1; 86(1): 64-71.
2. **Erectile Dysfunction Guidance** web site: EBRT and Viagra. [http://edguidance.com/viagra/.](http://edguidance.com/viagra/)
3. Kosuri S, Aktar NH, Smith M, et al., **Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radio-immunotherapy.** Advances in Urology, Vol. 2012 (2012), Art ID 921674.
4. Pound CR, Partin AW, Eisenberger MA, et al., **Natural History of Progression after PSA Elevation Following Radical Prostatectomy.** JAMA 1999; 281:1591–7. PMID: 10235151.
5. Roehl KA, Han M, Ramos CG, et al., **Cancer Progression and Survival Rates Following Anatomical Radical Retropubic Prostatectomy in 3,478 Consecutive Patients: Long-Term Results.** *J Urol.* 2004; 172:910–14. PMID: 15310996.
6. See 5 above.
7. Garnick MB. **How to handle a relapse after treatment for prostate cancer.** Prostate Knowledge, Harvard Medical School. [http://www.harvardprostateknowledge.org/ how-to-handle-a-relapse-after-treatment-for-prostate-cancer.](http://www.harvardprostateknowledge.org/%20how-to-handle-a-relapse-after-treatment-for-prostate-cancer.%20)
8. Mangar SA, Huddart RA, Parker CC, et al., **Technological advances in radiotherapy for the treatment of localised prostate cancer.** Eur J Cancer. 2005 Apr; 41(6): 908-21.
9. **IMRT for prostate cancer.** Cancer Centers of America web site. [http://www.cancercenter.com/prostate-cancer/imrt/.](http://www.cancercenter.com/prostate-cancer/imrt/)
10. Kirichenko, A, et al., **IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects.** <http://psychcentral.com/news/archives/2006-11/fccc-iv3110106.html>.
11. Sharma, NK, Li, T., Chen, DY., et al., **IMRT Reduces Gastrointestinal Toxicity in Patients treated with ADT for Prostate Cancer.** Int J Rad Onco•Biology•Physics 2011; 80 (2): 437-444.
12. Zhou GX, Xu SP, Dai XK, et al., **Clinical dosimetric study of three radiotherapy techniques for postoperative breast cancer: Helical Tomotherapy, IMRT, and 3D-CRT.** Technol Cancer Res Treat. 2011 Feb; 10(1):15-23.
13. **RapidArc**® **- the next dimension in speed and precision.** [http://www.varian.com/euen/oncology/treatments/treatment\_techniques/rapidarc/.](http://www.varian.com/euen/oncology/treatments/treatment_techniques/rapidarc/)
14. **Stereotactic Body Radiotherapy for Primary Management of Early-Stage, Low- to Intermediate-Risk Prostate Cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.** <www.redjournal.org/article/S0360-3016(09)03543-3/fulltext>
15. UCLA Health. Radiation Oncology UCLA. **Stereotactic Body Radiotherapy for Prostate Cancer.**

<http://radonc.ucla.edu/body.cfm?id=244.>

1. King CR, James D. Brooks JD, et al., **Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-risk Prostate Cancer.** [http://radonc.ucla.edu/workfiles/SBRT/Prostate\_SBRT\_Patient\_Info.pdf](http://radonc.ucla.edu/workfiles/SBRT/Prostate_SBRT_Patient_Info.pdf%20)
2. Yu JB, Cramer LD, Herrin J, et al., **SBRT Vs IMRT for Prostate Cancer: Comparison of Toxicity.** JCO March 10, 2014 JCO.2013.53.8652.
3. West Australian Dept. of Health. Sir Gairdner Hospital, Perth, West Australia, Australia. **CyberKnife Robotic Radiosurgery System Patient Information Sheet**. <www.scgh.health.wa.gov.au/OurServices/CancerCentre/RadiationOncology/Patient/pdf/CyberKnifePatientInformationSheet.pdf.>
4. Zietman AL, DeSilvio ML, Slater JD, et al., **Comparisons of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.** J. A. M. A. 294 (10, 1233-1239 (2005).
5. Foote RL, Stafford SL, Petersen IA, et al., **The clinical case for proton beam therapy.** Radiation Oncology 2012, 7:174
6. Efstathiou JA. **A Landmark Study Compares Proton Beam Therapy with Standard Radiation Therapy.** Advances at Mass. General Cancer Center - Fall 2013. [www.massgeneral.org/cancer/assets/advancesincancer/ADVQ413\_Cancer\_Proton%20Beam%20Therapy%20 (2).pdf.](www.massgeneral.org/cancer/assets/advancesincancer/ADVQ413_Cancer_Proton%20Beam%20Therapy%20%20(2).pdf.)
7. Talcott A, Rossi C, Shipley WU, et al., **Patient-Reported Long-term Outcomes After Conventional and High-Dose Combined Proton and Photon Radiation for Early Prostate Cancer.** JAMA. 2010; 303(11): 1046-1053.
8. As 21 above.
9. Chung CS, Keating N, Yock T, Tarbell N. **Comparative Analysis of Second Malignancy Risk in Patients Treated with Proton Therapy versus Conventional Photon Therapy.** Int J Radiat Oncol Biol Phys. Vol. 72, Supp, PS8, Sept 2008.
10. Fontenot JD, Lee AK, Newhauser WD. **Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer.** Int J Radiat Oncol Biol Phys. 2009 Jun 1; 74(2): 616-22.
11. Allen AM, Pawlicki T, Dong L. **An evidence-based review of proton beam therapy: the report of ASTRO's emerging technology committee.** Radiother Oncol. 2012 Apr; 103(1): 8-11.
12. Efstathiou, JA, Gray PJ, Zietman AL. **Proton Beam Therapy and Localised Prostate Cancer: Current Status and Controversies.** British Journal of Cancer 108, no. 6 (April 2, 2013): 1225–1230.
13. Lawenda BD. Proton Beam Therapy: **The Rolls Royce of Radiation Oncology.** [www.integrativeoncology-essentials.com/2013/03/proton-beam-therapy-the-rolls-royce-of-radiation-oncology/#sthash.6sONAuAD.aq4qTINH.dpuf.](www.integrativeoncology-essentials.com/2013/03/proton-beam-therapy-the-rolls-royce-of-radiation-oncology/%23sthash.6sONAuAD.aq4qTINH.dpuf.)
14. Grimm P, Billiet I, Bostwick D, et al., **Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high-risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group**. BJU Int. 2012 Feb; 109 Suppl 1:22-9.
15. Langley SEM, Laing RW. **4D Brachytherapy - a novel real-time prostate brachytherapy technique using stranded and loose seeds.** BJU Int. Vol. 109, Issue Supp s1, pages 1–6, Feb 2012. <http://www.4dbrachytherapy.com/index.php/overview.>
16. Hsu I-Chow, Yamada Y, Vigneault E, Pouliot J. **Generalized Criteria for the use of Brachytherapy in the treatment of Prostate Cancer August 2008.** American Brachytherapy Society Prostate High-Dose Rate Task Group. <www.americanbrachytherapy.org/guidelines/HDRTaskGroup.pdf.>
17. Hofman MS, et al., **[177Lu]-PSMA-617 radionuclide treatment in patients with mCRPC.** Lancet Oncology 2018 Jun, 19(6):825-833.
18. Kratochwil C, et al., **Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617.** J Nucl Med 2018; 59:795-802.
19. Efstathiou, Jason A., **External Beam Radiation Therapy for High-Risk/Locally Advanced Prostate Cancer: The Shifting Landscape.** April 12, 2019. Accessed Aug 2019. <https://grandroundsinurology.com/external-beam-radiation-therapy-for-high-risk-locally-advanced-prostate-cancer-the-shifting-landscape/>
20. Fiorillo, M., **Doxycycline, Azithromycin and Vitamin C: A potent combination therapy for targeting mitochondria and eradicating cancer stem cells.** Aging (Albany NY). 2019 Apr 19;11(8):2202-2216.

###### 38. Jackson, WC., et al., **Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.** Int. J. Radiat. Oncol. Biol. Phys 2019 Jul 15;104(4)778-789.

**Chapter 9. Hyperthermia**

1. Lieberman S. **A Review of Whole-Body Hyperthermia and the Experience of Klinik St.Georg,** Townsend Letter, Aug/Sept 2009, <http://kstg.net/e/publications/pdf/a_review_of_whole_body_hyperthermia_and_the_experience_of_klinik-st-georg.html.>
2. van der Zee J., **Heating the patient: a promising approach?** Ann Oncol. 2002 Aug; 13(8):1173-84.
3. Douwes FR, Lieberman S., **Radio-frequency Transurethral Hyperthermia and Complete Androgen Blockade**. Jnl of Alternative & Complementary Therapies 7:6: 291-295, 2001.
4. Oleson RO, Samulski TV, Leopold KA, et al., **Sensitivity of hyperthermia trial outcomes to temperature and time: Implications for thermal goals of treatment.** Int Jour of Rad Onco. Biol. Physics Vol. 25, Issue 2, 15 Jan 1993.
5. **The Science of Hyperthermia,** Albathermia Web Site, <www.albahyperthermia.com/hyperthermia-overview.html.>
6. Falk MH, Issels RD., **Hyperthermia in oncology.** Int J Hyperthermia. 2001 Jan-Feb; 17(1):1-18.

**Chapter 10. Cryosurgery**

1. Babaian RJ, Donnelly B, Bahn D, et al. (Panel Members). **Best Practice Policy Statement on Cryosurgery for the Treatment of Localized Prostate Cancer.** American Urological Association. <www.auanet.org/education/guidelines/cryosurgery.cfm.>
2. Heidenreich A, **Locally Recurrent Prostate Cancer Following Radiation Therapy: To Cut or To Freeze?** European Urology, Volume 64 Issue 1, July 2013, Pages 8-10.
3. Bahn DK, Lee F, Badalament R, et al., **Targeted Cryoablation of the Prostate: 7-Year Outcomes in the Primary Treatment of Prostate Cancer.** Urology Vol 60, (Suppl 2A): 3–11, 2002.
4. Ex - Director of the Prostate Cancer Institute, St. George Hospital, Sydney, Australia. **Comments on the Institute’s web site**. <http://www.prostatecancer.org.au/PCI/News.html.>
5. Onik G, Vaughan D, Lotenfoe R, et al., **‘Male lumpectomy’: focal therapy for prostate cancer using cryoablation.** Urology. 2007 Dec; 70(6 Suppl): 16-21.

**Chapter 11. High Intensity Focussed Ultrasound**

1. Roundy N. **HIFU Treatment Data is Maturing.** PCRI Insights, March 2011, Vol. 14: No 1. [http://prostate-cancer.org/PDFs/Is14-1\_p14-20.pdf.](http://prostate-cancer.org/PDFs/Is14-1_p14-20.pdf.%20)
2. Brosman S. **HIFU – Not Ready for Prime Time.** PCRI Insights, March 2011, Vol. 14: No 1.
3. Lukka H, Waldron T, Chin J, et al**., High-intensity focused ultrasound for prostate cancer: a systematic review.** Clin Oncol (R Coll Radiol). 2011 Mar; 23(2): 117-27.
4. Ahmed HU, Freeman A, Kirkham A. **Focal therapy for localized prostate cancer: a phase I/II trial.** J Urol. 2011 Apr; 185(4): 1246-54.
5. Hindley RG, Dickinson L, Freeman A. **Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.** The Lancet Oncology, Vol. 13, Issue 6, Pg 622 - 632, June 2012.
6. Cordeiro ER, Cathelineau X, Thüroff S, et al., **High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer.** BJU Int. 2012 Nov; 110(9): 1228-42.
7. Obyn C, Mambourg F. **Assessment of high intensity focused ultrasound for the treatment of prostate cancer.** Acta Chir Belg. 2009 Oct; 109(5): 581-6.
8. Dickinson L, Hu Y, Ahmed HU, et al. **Image-Directed, Tissue-Preserving Focal Therapy of Prostate Cancer: A Feasibility Study of a Novel Deformable MR-US Registration System.** BJU Int. Vol. 112, Issue 5, pages 594–601, Sept 2013.
9. Scionti S. **Targeted Focal Prostate Cancer Treatment.** Scionti Prostate Centre Web Site: <www.drscionti.com/targeted-focal-prostate-cancer-treatment.>

**Chapter 12. Focal Laser Ablation**

1. **Smilow Comprehensive Prostate Cancer Centre,** NYULMC: <http://prostate-cancer.med.nyu.edu/treatment/focal-laser-ablation-prostate-cancer.>
2. Turkbey B, Ravizzini G, Mani H, et al.,**3T MR Imaging of the Prostate Gland: What the Urologist Needs to Know.** National Cancer Institute, NIH, USA. <www.baristurkbey.com/images/prostate%20poster.pdf.>
3. Costa DN, Bloch BN, Yao DF, et al., **Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies.** Magnetic Resonance Imaging Jul 2013, 31(6); 947-952.
4. Sperling D, **Sperling Prostate Centre** <http://sperlingprostatecenter.com/>
5. Oto A, Sethi I, Karczmar G, et al., **MR imaging-guided focal laser ablation for prostate cancer: phase I trial**. Radiology. 2013 Jun; 267(3): 932-40.
6. **Smilow Comprehensive Prostate Cancer Centre,** NYULMC: <http://prostate-cancer.med.nyu.edu/treatment/focal-laser-ablation-prostate-cancer.>
7. Mottet N, Bastian PJ, Bellmunt J, et al., **Guidelines on Prostate Cancer Updated April 2014.** European Urology Association. <http://www.uroweb.org/gls/pdf/1607%20Prostate%20Cancer_LRV3.pdf.>
8. Mottet N, Bastian PJ, Bellmunt J, et al., **Pocket Guidelines on Prostate Cancer Updated April 2014.** European Urology Association. <http://www.uroweb.org/gls/pockets/english/PCProstate%20Cancer_LR.pdf>

**Chapter 13. Hormone Therapy**

1. **Xtandi Phase 111 Clinical Trial Web Site.** <https://www.xtandihcp.com/phase-3-trial-design.>
2. Higano CS, et al., **Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer.** Cancer. <https://doi.org/10.1002/cncr.32445.>
3. **Abiraterone: a story of scientific innovation and commercial partnership.** Institute of Cancer Research, UK. <http://www.icr.ac.uk/press/recent_featured_articles/Story_Abiraterone/index.shtml.>

**Chapter 14. Chemotherapy and Immunotherapy**

1. **Metastatic Cancer**. National Cancer Institute Fact Sheet. <http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic.>
2. **What biophosphonates are.** Cancer Research UK. <http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/bisphosphonate/what-bisphosphonates-are.>
3. Sartor O, Eisenberger M, Kattan MW, et al., **Unmet Needs in the Prediction and Detection of Metastates in Prostate Cancer**. The Oncologist Express, May 6, 2013.
4. Sweeney C, Chen Y, Carducci MA, et al., **Impact on overall survival (OS) with chemo-hormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mHSPC): an ECOG-led phase 3 randomized trial.** J Clin Oncol. 2014; 32:5s (suppl; abstr LBA2).
5. **Bavarian Nordic Initiates Pivotal Phase 3 Trial of** **PROSTVAC® Prostate Cancer Immunotherapy.** <http://ci.bavarian-nordic.com/media/news.aspx?news=1919.>
6. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. **Exosomes: proteomic insights and diagnostic potential.** Expert Rev Proteomics. 2009 Jun; 6(3): 267-83.
7. Giusti I, Dolo V. **Extracellular vesicles in prostate cancer: new future clinical strategies?** Biomed Res Int. 2014; 2014: 561571.

# Yi-Tsung Lu, et al., Current status of liquid biopsies for the detection and management of prostate cancer. [Cancer Manag Res](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559244/). 2019; 11: 5271–5291.

**Chapter 15. mCRPC, Genetics and Precision Medicine**

1. Marckini R. ***Brotherhood of the Balloon*.** <www.protonbob.com/proton-treatment-homepage.asp.>

1. Pedro Isaacsson Velho, et al., **Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer.** European Urology, June 2019.

**Chapter 19. Complementary Therapies**

1. Lee MS, Ernst E. **Systematic reviews of t'ai chi: an overview.** Br J Sports Med. Aug 2012 46(10): 713-8.
2. Madsen MV, Gøtzsche PC, Hróbjartsson A. **Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups.** BMJ. 2009 Jan 27; 338: a3115.
3. Jonas WB, Gaddipati JP, Rajeshkumar NV, et al., **Can homeopathic treatment slow prostate cancer growth?** Integr Cancer Ther. 2006 Dec; 5(4):343-9.
4. **Shark Cartilage.** American Cancer Society. <www.cancer.org/treatment/treatmentsandsideeffects/complementaryandalternativemedicine/pharmacologicalandbiologicaltreatment/shark-cartilage.>
5. Adlerova L, Bartoskova A, Faldyna M. **Lactoferrin: a review.** Veterinarni Medicina, 53, 2008(9): 457–468.
6. Gibbons JA, Kanwar RK, Kanwar JR. **Lactoferrin and cancer in different cancer models.** Front Biosci (Schol Ed). 2011 Jun 1; 3:1080-8.

**Chapter 20. Diet and Nutrition**

1. Vasconcelos A, Santos T, Ravasco P, Neves PM. **Dairy Products: Is There an Impact on Promotion of Prostate Cancer? A Review of the Literature.** Front Nutr. 2019 May 14; 6:62. doi: 10.3389/fnut.2019.00062.
2. Macdonald R, Tacklind JW, Rutks I, Wilt TJ. **Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.** BJU Int. Vol. 109, Issue 12, pages 1756–1761, June 2012.
3. Khana N, Adhamia VM, Mukhtara HV. **Review: Green Tea Polyphenols in Chemoprevention of Prostate Cancer: Preclinical and Clinical Studies.** Nutrition and Cancer, Volume 61, Issue 6, 2009.
4. von Holtz RL, Fink CS, Awad AB. **beta-Sitosterol activates the sphingomyelin cycle and** **induces apoptosis in LNCaP human prostate cancer cells.** Nutr Cancer. 1998; 32(1): 8-12.
5. Awad AB, Burr AT, Fink CS. **Effect of resveratrol and beta-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells.** Prostaglandins Leukot Essent Fatty Acids 72 (3): 219-26, 2005.
6. Obermüller-Jevic UC, Olano-Martin E, Corbacho AM, et al., **Lycopene inhibits the growth of normal human prostate epithelial cells in vitro.** J Nutr. 2003 Nov; 133(11): 3356-60.
7. Zhang X-K. **Vitamin A and apoptosis in prostate cancer.** Endocrine-Related Cancer (2002) 9 87–102.
8. Gaziano JM, Sesso HD, Christen WG, et al., **Multivitamins in the prevention of cancer in men: The Physicians' Health Study II randomized controlled trial.** JAMA. 2012 Nov 14; 308(18): 1871-80.
9. Ho E. **Zinc and Antioxidants in Cancer Chemoprevention.** Linus Pauling Institute, Oregon State University. <http://lpi.oregonstate.edu/CCP/zinc-cancer.html.>
10. Richman EL, Kenfield SA, Chavarro JE, et al., **Men with Prostate Cancer Should Eat Healthy Vegetable Fats.** UC San Francisco. JAMA Internal Medicine on line 10 June 2013.
11. Richman EL, Kenfield SA, Chavarro JE, et al., **Fat Intake After Diagnosis and Risk of Lethal Prostate Cancer** **and All-Cause Mortality.** JAMA Intern Med. 2013; 173(14): 1318-1326.
12. Stacewicz-Sapuntzakis M, Borthakur G, Burns JL, Bowen PE. **Correlations of dietary patterns with prostate health.** Mol Nutr Food Res. 2008 Jan; 52(1): 114-30.
13. Itsiopoulos C, Hodge A, Kaimakamis, M. **Can the Mediterranean diet prevent prostate cancer?** Mol Nutr Food Res. 2009 Feb; 53(2):227-39.
14. Sonoda T, Nagata Y, Mori M, et al., **A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet.** Cancer Sci. 2004 Mar; 95(3): 238-42.
15. Mori M, Masumori N, Fukuta F, et al., **Traditional Japanese diet and prostate cancer.** Mol Nutr Food Res. 2009 Feb; 53(2):191-200.
16. Pantuck AJ, Leppert JT, Zomorodian N, et al., **Phase II Study of Pomegranate Juice for Men with Rising PSA following Surgery or Radiation for Prostate Cancer**. Clinical Cancer Research (Vol. 12 p 4018-4026) 2006.

**Chapter 22. Future Developments**

1. Costello LC, Franklin RB. **A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?**<https://www.ncbi.nlm.nih.gov/pubmed/30828702>

2. Costello LC. **The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer.** <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641560/>

**Chapter 23. The Role of Support Groups**

1. Marckini R. ***Brotherhood of the Balloon*.** <www.protonbob.com/proton-treatment-homepage.asp.>

**Chapter 29. Enter the Case for Hyperthermia**

1. Douwes FR, Lieberman S., **Radio-frequency Transurethral Hyperthermia and Complete Androgen Blockade.** Jnl of Alternative & Complementary Therapies 7:6: 291-295, 2001.